BioCentury
ARTICLE | Clinical News

GlycoMimetics: Pfizer will start delayed rivipansel trial

April 8, 2015 12:31 AM UTC

GlycoMimetics Inc. (NASDAQ:GLYC) said partner Pfizer Inc. (NYSE:PFE) will begin a Phase III trial in mid-2015 of rivipansel ( GMI-1070) to treat vaso-occlusive crisis (VOC) in patients with sickle cell disease. Pfizer originally planned to begin the trial in 2H14, but delayed it last fall because of an unspecified manufacturing issue. GlycoMimetics said FDA has since discussed the issue with Pfizer and reviewed amended study documents (see BioCentury Extra, September 26, 2014).

GlycoMimetics said it is due a $20 million milestone payment from Pfizer when the first patient is dosed in the Phase III trial. Pfizer obtained exclusive, worldwide rights to rivipansel from GlycoMimetics in 2011; it paid GlycoMimetics a $15 million milestone in May 2014. ...